The Buzz, Issue #15 is now out! This month, we highlight a survey of Canadian practice patterns in atopic dermatitis, a Canadian position statement on preventing food allergy in high-risk infants, and the World Allergy Organization’s guidelines on immunotherapy for cow’s milk allergy. We also feature a Canadian survey of attitudes towards COVID-19 vaccination among patients with primary immunodeficiency and look into the sensitivity and specificity of using TPO and IgE as diagnostic biomarkers for autoimmune CSU.
The Buzz Issue #15, July 2022 edition, will be sent to all HIVE members by email on Mon, June 27th, and can be accessed online here. To view all issues of The Buzz, go to thehivecommunity.org/the-buzz
The Buzz, Issue #14 is now out! In this month’s issue, we highlight a possible new predictive biomarker for severe anaphylaxis in children, the use of direct oral challenge to de-label penicillin allergy during pregnancy, and three publications in atopic dermatitis: new data with the JAK1-selective inhibitor abrocitinib, a structured appraisal of the clinical practice guidelines, and a metaanalysis of the literature on the use of dilute bleach baths.
The Buzz Issue #14, June 2022 edition, will be sent to all HIVE members by email on Mon, May 30th, and can be accessed online here. To view all issues of The Buzz, go to thehivecommunity.org/the-buzz
The HIVE Refresh!
Dear HIVE members, We looked for your feedback, reflected upon it and refreshed our purpose and process to go beyond Chronic Spontaneous Urticaria (CSU) to include keywords of common interest to allergists, immunologists and dermatologists. You will see this reflected in your weekly HIVE email digest, in the “New Articles From Your Sources” section as…
The Buzz, Issue #13 is now out! This month’s publications look at peanut cross-contamination rates, the safety of second SARS-CoV-2 vaccine doses following an immediate allergic reaction to dose 1, the risk of thyroid autoimmunity in the setting of chronic urticaria, a review of cannabis-related allergy, and another scoping review about culprit drug identification.
The Buzz Issue #13, May 2022 edition, will be sent to all HIVE members by email on Mon, May 2nd, and can be accessed online here. To view all issues of The Buzz, go to thehivecommunity.org/the-buzz
The Buzz, Issue #12 is now out! This month, we look at publications in the areas of peanut cross-contamination rates, the safety of second SARS-CoV-2 vaccine doses following an immediate allergic reaction to dose 1, the risk of thyroid autoimmunity in the setting of chronic urticaria, a review of cannabis-related allergy, and another scoping review about culprit drug identification.
The Buzz Issue #12, April 2022 edition, will be sent to all HIVE members by email on Mon, April 4th, and can be accessed online here. To view all issues of The Buzz, go to thehivecommunity.org/the-buzz
The Buzz, Issue #11 is now out! This month, we look at the phase 3 dupilumab study of pediatric asthma patients, and feature two new real-world studies of peanut immunotherapy, an investigation into reproducibility of anaphylactic symptoms sequences and the new CSACI position statement on transitioning to 0.50mg epinephrine autoinjectors.
The Buzz Issue #11, March 2022 edition, will be sent to all HIVE members by email on Tues, March 22nd, and can be accessed online here. To view all issues of The Buzz, go to thehivecommunity.org/the-buzz
The Buzz, Issue #10 is now out! This issue features randomized studies for monoclonal antibodies in CSU, a look at how Canadian parents view oral food challenge, Canadians use of topical cannabinoids, and a scoping review for identifying drug culprits for adverse cutaneous drug reactions.
The Buzz Issue #10, December 2021 edition, will be sent to all HIVE members by email on Mon, December 27th, and can be accessed online here. To view all issues of The Buzz, go to thehivecommunity.org/the-buzz
The Buzz, Issue #9 is now out! This issue features adverse events following vaccination, a case series on complement measurements in hereditary angioedema, a retrospective analysis of psoriasiform lesion in children taking dupilumab, and two systematic reviews, one in chronic urticaria and the other in food allergy.
The Buzz Issue #9, November 2021 edition, will be sent to all HIVE members by email on Thurs, November 25th, and can be accessed online here. This edition covers: Vaccine pharmacovigilance and management of immune and non-immune adverse vaccine eventsC1-inhibitor and C4 as diagnostic markers in hereditary angioedemaPsoriasiform eruptions in children taking dupilumab for atopic…
The Buzz, Issue #8 is now out! This issue features new international urticaria guidelines, a trial of convalescent plasma in COVID-19, and new publications on peanut immunotherapy, food allergy desensitization, and combination treatment for allergic rhinitis.
The Buzz Issue #8, October 2021 edition, will be sent to all HIVE members by email on Tuesday, October 26th, and can be accessed online here. This edition covers: Updated guidelines for chronic urticariaThe CONCOR-1 study of convalescent plasma for COVID-19 treatmentPost-hoc analysis of allergic reaction severity from a peanut immunotherapy studyDupilumab and subcutaneous immunotherapy…
The Buzz, Issue #7 is now out! In this issue we feature five new publications with high clinical relevance for Canadian allergists.
The Buzz Issue #7, September 2021 edition, will be sent to all HIVE members by email on Tuesday, September 14th, and can be accessed online here. This edition covers: Challenges and success in implementing the findings from LEAPUsing graded oral challenge to confirm hypersensitivity to amoxicillinClinical and demographics characteristics of HAE patients in CanadaComorbid autoimmune…
Loading…
Something went wrong. Please refresh the page and/or try again.
The HIVE Community 